Our leading subject matter experts share their insightful analysis and points of view to help you stay abreast of industry trends
For years, the pharmaceutical industry has measured R&D productivity at the wrong moment in time: FDA approval. However, approval is only one checkpoint. The harder questions come afterwards: Will payers…
Pharma companies are deploying AI tools across a broad range of market access functions, from payer account strategy to contracting and beyond. According to our 2026 State of Patient Access…
Biosimilar adoption and vertical integration used to be separate challenges for manufacturers — one focused on formulary competition, the other on navigating payer consolidation. New Q2 2026 MMIT Indices research…
For years, immunology has ranked as one of the top therapeutic areas by value, with year-over-year growth driven by blockbuster biologics for conditions like rheumatoid arthritis (RA), psoriasis, and inflammatory…
After years of record growth driven by subsidized premiums, enrollment in Affordable Care Act (ACA) exchange plans plummeted this year from its all-time high of 24.3 million members in 2025.…
There is no doubt that payers in the U.S. are investing heavily in AI, but there is much uncertainty about how this technology is currently deployed. While the industry’s AI…
More than 10,000 attendees visited Las Vegas last week for Asembia’s ASX26 Summit. Along with meeting with clients and hosting the Specialty Pharmacy Patient Choice Awards, MMIT representatives attended many…
This article was originally published in Pharmaceutical Executive on April 6, 2026.
Pharmacy benefit managers (PBMs) sit at the center of an increasingly complex web of relationships among manufacturers, health…
To better understand what 2026 might bring, we asked three MMIT market access experts to share their perspectives on upcoming market shifts. Read on for key insights into the year…
To better understand what 2026 might bring, we asked three MMIT market access experts to share their perspectives on upcoming market shifts. Read the first of this two-part series for…
